the United Kingdom -based start-up Reverie , a graduate of the Y HBO accelerator, aims to speed up drug development by using machine learning and artificial intelligence (AI) to become a fully fledged "molecule-as-a-service" company. Reverie Labs uses machine learning to analyse molecule properties and how they react in the human body, offering suggestions and alternatives to scientists looking to begin clinical trials. The cloud-based system integrates into first -party workflows, and the company has already partnered with scientists and biotech firms working on treatments for flu and cancer.
Boston-based start-up Reverie Labs, a graduate of the Y Combinator accelerator, aims to speed up drug development by using machine learning and artificial intelligence (AI) to become a fully fledged "molecule-as-a-service" company. Reverie uses machine learning to analyse molecule properties and how they react in the human body, offering suggestions and alternatives to scientists looking to begin clinical trials. The cloud-based system integrates into third-party workflows, and the company has already partnered with scientists and biotech firms working on treatments for flu and cancer.